- Conditions
- Heparin-induced Thrombocytopenia
- Interventions
- VLX-1005, Argatroban
- Drug
- Lead sponsor
- Veralox Therapeutics
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Safety and Tolerability in Healthy Volunteers
- Interventions
- VLX-1005, Placebo
- Drug
- Lead sponsor
- Veralox Therapeutics
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia
- Interventions
- VLX-1005, Placebo
- Drug
- Lead sponsor
- Veralox Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 14
- States / cities
- Stanford, California • Aurora, Colorado • New Haven, Connecticut + 9 more